Want to contact a Washington, DC Baraclude lawyer? ...Get a free case evaluation from one of our Washington, DC Baraclude lawyers now.
Baraclude - News Articles
-
Feb 8, 2007
CNW Telbec (Communiqués de presse), Canada -
8 /CNW Telbec/ - Bristol-Myers Squibb Canada announced today that Baraclude(TM), a drug administered orally to treat chronic hepatitis B virus infection, " statedJean-Paul Bédard, Vice-President, Corporate Affairs. About Bristol-Myers Squibb Canada Bristol-Myers Squibb Canada is ... -
Jan 29, 2007
CNNMoney.com -
including Orencia, a treatment for rheumatoid arthritis, Sprycel, a treatment for two types of leukemia, and the hepatitis drug Baraclude. Chris Schott, analyst for Bank of America, said in a published note that the merger, if it happens, would provide ... -
Jan 19, 2007
Med Ad News (subscription), PA -
s Baraclude, Tyzeka’s rapid and profound viral suppression and favorable safety profile are expected to have a positive effect on market acceptance and patient compliance. The worldwide hepatitis B virus nucleoside analog market generates about $450 million in sales each year and ... -
Oct 31, 2006
PipelineReview.com (press release), Spain -
MA, USA | Oct 30, 2006 | Bristol-Myers Squibb Company (NYSE: BMY) today announced three-year results of the BARACLUDE(R) (entecavir) resistance monitoring program, which found the incidence of resistance to be low among patients treated with BARACLUDE in nucleoside-naive studies (n=673). ... -
Oct 30, 2006
PR Newswire (press release), NY -
30 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced three-year results of the BARACLUDE(R) (entecavir) resistance monitoring program, which found the incidence of resistance to be low among patients treated with BARACLUDE in nucleoside-naive studies (n=673). ... -
Oct 31, 2006
Medical News Today (press release), UK -
hepatitis B e-antigen (HBeAg) positive patients, showing that patients receiving the oral antiviral therapy BARACLUDE(R) (entecavir) demonstrated greater viral load reduction at weeks 12 (primary endpoint) and 24 than patients treated with adefovir. Specifically, 45 percent of BARACLUDE-treated ... -
Oct 30, 2006
Earthtimes.org -
in this cohort to undetectable levels of viral load at three years is encouraging and these data provide important information about BARACLUDE for healthcare professionals," said Hugo Cheinquer, M.D., Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil.google_ad_client = "pub-6607258750979944";google_ad_width = 250;google_ad_height ... -
Oct 30, 2006
Earthtimes.org -
"Despite the fact that the hepatitis B virus is constantly changing, BARACLUDE creates a high barrier to resistance development in nucleoside-naive patients , as demonstrated by the less than one percent resistance rate through three years," said Richard Colonno, Ph.D., vice president ... -
Oct 31, 2006
PharmaLive.com (press release), PA -
PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced data from a three-year cohort (ETV-022/901, n=119), which showed BARACLUDE(R) (entecavir ) suppressed viral load to undetectable levels in 90 percent of nucleoside-naive chronic hepatitis B e-antigen (HBeAg) positive patients at ... -
Oct 31, 2006
Medical News Today (press release), UK -
Bristol-Myers Squibb Company (NYSE: BMY) today announced data from a three-year cohort (ETV-022/901, n=119), which showed BARACLUDE(R) (entecavir) suppressed viral load to undetectable levels in 90 percent of nucleoside-naive chronic hepatitis B e-antigen (HBeAg) positive patients at week ...
-
Nov 2, 2006
Medical News Today (press release), UK -
Bristol-Myers Squibb Company (NYSE: BMY) today announced three-year results of the BARACLUDE® (entecavir) resistance monitoring program, which found the incidence of resistance to be low among patients treated with BARACLUDE in nucleoside-nave studies (n=673). Two patients, or less ... -
Monday, October 30, 2006
PharmaLive.com (press release), PA -
BOSTON, October 30, 2006 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced results of an open-label, randomized study of 65 antiviral naive chronic hepatitis B e-antigen (HBeAg) positive patients, showing that patients receiving the oral antiviral therapy BARACLUDE(R) (entecavir) demonstrated ... -
Monday, October 30, 2006
Yahoo! News (press release) -
BOSTON, Oct. 30 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY - News) today announced results of an open-label , randomized study of 65antiviral naive chronic hepatitis B e-antigen (HBeAg) positive patients,showing that patients receiving the oral antiviral therapy ... -
Monday, October 30, 2006
MarketWatch -
Bristol-Myers Squibb Co. (BMY) said patients receiving Baraclude demonstrated greater viral-load reduction at 12 and 24 weeks than patients on adefovir, according to a study of 65 patients with chronic hepatitis B. ... -
Oct 28, 2006
Trading Markets, CA -
monotherapies for HBV are GlaxoSmithKline's Epivir-HB (lamivudine), Gilead Sciences' Hepsera (adefovir), Bristol-Myers Squibb's Baraclude (entecavir), Schering ... -
Oct 27, 2006
PharmaLive.com (press release), PA -
SAN FRANCISCO--(BUSINESS WIRE)--Oct 27, 2006 - A class action lawsuit has been filed by Hersh & Hersh, Miller & Associates and Whatley Drake & Kallas, LLC on behalf of third party payer, claiming that the Defendants rushed the drug to market and then launched an ... -
Sunday, October 29, 2006
Lawfuel (press release), New Zealand -
SAN FRANCISCO-- LAWFUEL - Law News, Law Jobs --A class action lawsuit has been filed by Hersh & Hersh, Miller & Associates and Whatley Drake & Kallas, LLC ... -
Oct 27, 2006
Genetic Engineering News (press release), NY -
A class action lawsuit has been filed by Hersh & Hersh, Miller & Associates and Whatley Drake & Kallas, LLC against Bristol-Myers Squibb and Sanofi-Aventis, a ... -
Oct 27, 2006
Therapeutics Daily (subscription) (press release), PA -
A potential class-action lawsuit was filed alleging Bristol-Myers Squibb Co. (BMY) and Sanofi-Aventis (SNY) sold anti-coagulant Plavix knowing it increased the risk of heart attacks and strokes. The lawsuit was filed against the New ... -
Oct 27, 2006
United Press International -
SAN FRANCISCO, Oct. 27 (UPI) -- Bristol-Myers Squibb faces a class action lawsuit alleging it continued to market Plavix, even though it was aware of health risks. The plaintiffs, represented by Hersh & Hersh, Miller & Associates and Whatley ...
Want to contact a Washington, DC Baraclude lawyer? ...Get a free case evaluation from one of our Washington, DC Baraclude lawyers now.
Pages: Previous 1 2 3 4 5 6
